On October 8, Chase Biotech announced the completion of Pre-A round financing of more than 50 million yuan. This round was led by Shenzhen Venture Capital, followed by Guangdong Traditional Chinese Medicine Health Fund, Nanshan New Investment, and Zero Venture Capital. This round of financing will mainly be used for core product development and engineering, verification of key application scenarios, and further exploration of AI-driven technology service models.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.